Selected article for: "control group and patient group"

Author: da Cunha, Gilmara Franco; de Souza, Fernando Henrique Carlos; Levy-Neto, Maurício; Shinjo, Samuel Katsuyuki
Title: Chloroquine diphosphate: a risk factor for herpes zoster in patients with dermatomyositis/polymyositis
  • Document date: 2013_5_23
  • ID: s9mqzqu4_6
    Snippet: Study population, clinical assessment and data collection. Between January 1991 and January 2012, 230 consecutive patients with DM or PM and who fulfilled at least four of the five Bohan and Peter (2) criteria were followed at a tertiary hospital. Twenty-four subjects (10.4%) in this group had histories of HZ. Of the remaining patients without HZ, a control group of 48 patients (two controls for every HZ patient) was formed and matched by gender,.....
    Document: Study population, clinical assessment and data collection. Between January 1991 and January 2012, 230 consecutive patients with DM or PM and who fulfilled at least four of the five Bohan and Peter (2) criteria were followed at a tertiary hospital. Twenty-four subjects (10.4%) in this group had histories of HZ. Of the remaining patients without HZ, a control group of 48 patients (two controls for every HZ patient) was formed and matched by gender, disease type (DM or PM), age at the onset of myositis and disease duration. The study was approved by the local Research Ethics Committee.

    Search related documents:
    Co phrase search for related documents
    • clinical assessment and control group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical assessment and disease type: 1, 2, 3
    • consecutive patient and disease type: 1
    • control group and disease myositis: 1
    • control group and disease myositis duration: 1
    • control group and disease myositis duration onset: 1
    • control group and disease myositis duration onset age: 1
    • control group and disease type: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • control group and group subject: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • control group and remain patient: 1
    • disease type and group subject: 1
    • disease type and PM DM disease type: 1
    • disease type and PM DM disease type gender: 1
    • HZ history and HZ patient: 1